α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

Death-associated Protein Kinase 1 Phosphorylates α-Synuclein at Ser129 and Exacerbates Rotenone-induced Toxic Aggregation of α-Synuclein in Dopaminergic SH-SY5Y Cells

Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease

Frontiers The Role of Lipids in the Initiation of α-Synuclein Misfolding

Full article: Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease

Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease

Alpha Synuclein Assay

Frontiers Modeling Parkinson's Disease With the Alpha-Synuclein Protein

Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies

Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease

Parkinson's Study Finds New Compound that Can Inhibit Alpha-Synuclein

IJMS, Free Full-Text